Home » Stocks » RZLT

Rezolute, Inc. (RZLT)

Stock Price: $15.23 USD 0.63 (4.32%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 127.21M
Revenue (ttm) n/a
Net Income (ttm) -18.87M
Shares Out 5.87M
EPS (ttm) -3.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $15.23
Previous Close $14.60
Change ($) 0.63
Change (%) 4.32%
Day's Open 14.21
Day's Range 14.15 - 15.23
Day's Volume 3,499
52-Week Range 11.99 - 20.99

News

There are no news available yet.

About RZLT

Rezolute, a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rez... [Read more...]

Industry
Biotechnology
Founded
2010
CEO
Nevan Elam
Employees
23
Stock Exchange
NASDAQ
Ticker Symbol
RZLT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Rezolute stock is "Buy." The 12-month stock price forecast is 31.50, which is an increase of 106.83% from the latest price.

Price Target
$31.50
(106.83% upside)
Analyst Consensus: Buy